Dr. Ryll has been an extremely active member of the EU Cancer Mision Board, and a pioneer in how good patient-researcher partnerships can boost the quality of research and the impact of its results. 

Yesterday, May 5th, at 3p.m. (Lisbon time), surgeon Pedro Gouveia was in the operating room, at the Breast Unit of the Champalimaud Foundation, in Lisbon, ready to start, as in so many other occasions, performing breast cancer surgery. Meanwhile, another surgeon from the same unit, the young Spaniard Rogelio Andrés-Luna, was attending the operation, and intervening, when needed, by supplying Pedro Gouveia with additional information to help him – and even guide his gestures. Everything seems to be business as usual – but it isn’t.

Zoom-In on Champalimaud: Ana Carolina Pádua

I hold a Master’s degree in Biomedical Engineering and a PhD in Molecular Biosciences from NOVA University, Lisbon. After completing my PhD project, I moved to Texas (USA) for an internship in High-Performance Computing. This experience allowed me to discover how supercomputers can contribute to making science more efficient and productive. 
 

This first Check Up is about the resurgence of cancer once the disease has been controlled by treatment. Do these terms used to talk about this problem mean the same thing?

Relapse, recurrence, recidivation. These words all mean the same thing in general terms: the disease is back.

However, there are differences between them when it comes to their clinical and medical meaning, which many people are not aware of.

This lecture is part of the "Champalimaud Cancer Talks" series, organised by the Champalimaud Foundation with the aim of offering the general public unique opportunities to hear the world's leading authorities in different fields related to cancer research and clinical practice. This time, Professor Hidde Ploegh will present his research work on: